Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 148-153

  Korkolopoulou, P ^a   Kaklamanis, L ^b,c   Pezzella, F ^a   Harris, A L ^c   Gatter, K C ^a  

^a Univ Department of Cellular Science

^b Nuffield Department of Pathology   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Lung carcinomas; MHC class I; TAP 1

Indexed keywords

ANTIBODY; BETA 2 MICROGLOBULIN; CARRIER PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; AGED; ALLELE; ANTIGEN PRESENTATION; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TUMOR CELL;

EID: 0030061067     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.28     Document Type: Article

References (49)

1. ALTMAN DG. (1991). Comparing groups: categorical data. In Practical Statistics for Medical Research. pp. 229-276. Chapman and Hall: London.
2. ARCE-GOMEZ B, JONES F, BARNSTABLE C, SOLOMON E AND BODMER W. (1978). The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for b2-microglobulin. Tissue Antigens, 11, 96-112.
3. ARMITAGE P AND BERRY G. (1987). Statistical Methods in Medical Research. Blackwell: Oxford.
4. BARNSTABLE CJ, BODMER WF, BROWN G, GAFFRE G, MILSTEIN C, WILLIAMS AF AND ZIEGLER A. (1978). Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens new tools for genetic analysis. Cell, 14, 9-20.
5. BODMER W. (1987). The HLA system: structure and function. J. Clin. Pathol., 40, 948-958.
6. BRODSKY F, BODMER W AND PARHAM P. (1979). Characterisation of a monoclonal anti-b2-microglobulin antibody and its use in the genetic and biochemical analysis if major histocompatibility antigens. Eur. J. Immunol., 9, 536-545.
7. CONCHA A, CABRERA T, RUIZ-CABELLO F AND GARRIDO F. (1991). Can the HLA phenotype be used as a prognostic factor in breast carcinoma? Int. J. Cancer, (suppl.6), 146-154.
8. CORDELL JL, FALINI B, ERBER WN, GHOSH AK, ABDULAZIZ Z, MCDONALD S, PULFORD KAF AND MASON DY. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem., 32, 219-229.
9. CROMME F, AIREY J, HEEMELS M, PLOEGH H, KEATING P, STERN P, MEIJER C AND WALBOOMERS J. (1994). Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179, 335-340.
10. DAAR A, FUGGLE S, FABRE J, TING A AND MORRIS P. (1984). The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation, 38, 287-293.
11. DÄMMRICH J, MÜLLER-HERMELINK HK, MATTNER A, BUCHWALD J AND ZIFFER S. (1990). Histocompatibility antigen expression in pulmonary carcinomas as indication of differentiation and of special subtypes. Cancer, 65, 1942-1954.
12. DAUSSET J. (1981). The major histocompatibility complex in man. Past, present and future concepts. Science, 213, 1469-1474.
13. DOYLE A, MARTIN J, FUNA K, GADGAR A, VARNEY D, MARTIN SE, LINNOILA I, CUCITTA F, MULSHINE J, BANN P AND MINNA J. (1985). Markedly decreased expression of class I histocompatibility antigens, protein and mRNA in human small-cell lung cancer. J. Exp. Med., 161, 1135-1151.
14. FESTENSTEIN H AND GARRIDO F. (1986). MHC antigens and malignancy (news). Nature, 322, 502-503.
15. FUNA K, GAZDAR AF, MINNA JD AND LINNOILA I. (1986). Paucity of b2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors. Lab. Invest., 55, 186-193.
16. GOEPEL JR, REES RC, ROGERS K, STODDARD CJ, THOMAS WEG AND SHEPHERD L. (1991). Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br. J. Cancer, 64, 880-883.
17. HAKEN R, LE BOUTELIER P, BARAD M, TRUJILLO M, MERCIER P, WIETZERBIN J AND LEMONIER FA. (1989). IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes. J. Immunol. 142, 297-305.
18. HUI K, GROSVELD F AND FESTENSTEIN H. (1984). Rejection of transplantable AKR leukaemic cells following MHC DNA-mediated cell transformation. Nature. 311, 750-752.
19. KAKLAMANIS L, GATTER KC, HILL AB, MORTENSEN N, HARRIS AL, KRAUSA P, MCMICHAEL A, BODMER JG AND BODMER WT. (1992). Loss of HLA class-1 alleles, heavy chains and b2-microglobulin in colorectal cancer. Int. J. Cancer, 51, 379-385.
20. KAKLAMANIS L, TOWNSEND A, DOUSSIS-ANAGNOSTOPOULOU I, MORTENSEN N, HARRIS AL AND GATTER KC. (1994). Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP1) in colorectal cancer. Am. J. Pathol., 145, 505-509.
21. KAPLAN EL AND MEIER P. (1958). Non parametric estimation from incomplete observations. J. Am. Stat. Ass., 53, 457-481.
22. KARRE K, LJUNGREN HG, PONTEC G AND KIESSLING R. (1986). Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature, 319, 675-678.
23. KELLY A, POWIS SH, KERR L-A, MOCKRIDGE I, ELLIOTT T, BASTIN J, UCHANSKA-ZIEGLER B, ZIEGLER A, TROWSDALE J AND TOWNSEND A. (1992). Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature, 355, 641-644.
24. KLEIJMEER MJ, KELLY A, GEUZE HJ, SLOT JW, TOWNSEND A AND TROWSDALE J. (1992). Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature, 357, 342-344.
25. LOPEZ-NEVOT MA, ESTEBAN F, FERRON A, OLIVIA MR, ROMERO C, HUELIN C, RUIZ-GABELLO F AND GARRIDO F. (1989). HLA-class-1 gene expression on human primary tumours and autologous metastases: demonstration of selective loss of HLA antigens on colorectal gastric and laryngeal carcinomas. Br. J. Cancer, 59, 221-226.
26. MCMICHAEL A, PARHAM P, RUST N AND BRODSKY F. (1980). A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17. Hum. Immunol., 1, 121-129.
27. MACHIN D AND GARDNER MJ. (1989). Calculating confidence intervals for survival time analyses. In Statistics with Confidence: Confidence Intervals and Statistical Guidelines, pp. 64-70. British Medical Journal: London.
28. MOLLER P, MOMBURG F, KORETZ K, MOLDENHAUER G, HERFORTH C, OTTO HF, HAMMERLING G AND SCHLAG P. (1991). Influence of major histocompatibility complex class-I and II antigens on survival colorectal carcinoma. Cancer Res., 51, 729-736.
29. MOMBURG F, DEGENER T, BACCHUS F, MOLDENHAUER G, HAMMERLING GJ AND MÖLLER P. (1986). Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal carcinoma. Int. J. Cancer, 38, 459-464.
30. MOMBURG F, ZIEGLER A, HARPPRECHT J, MÖLLER A, MOLDENHAUER G AND HAMMERLING G. (1989). Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J. Immunol., 142, 352-358.
31. ORGAD S, YANG SY, GAZIT E, RELIAS V, ZAIZOV R, LYSON S AND YUNIS EJ. (1985). Expression of extra class I major histocompatibility antigens on T-cell acute lymphoblastic leukemia (ALL) lymphoblasts. Hum. Immunol., 12, 133-141.
32. ORTMAN B, ANDROLEWICZ MJ AND CRESSWELL P. (1994). MHC class I/b2-microglobulin complexes associate with TAP transporters before peptide binding. Nature, 368, 864-867.
33. PARHAM P, BARNSTABLE CJ AND BODMER WF. (1979). Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C antigens. J. Immunol., 123, 342-349.
34. PETO R, PIKE MC, ARMITAGE P, BRESLOW NF, COX DR, HOWARD SV, MANTEL N, MCPHERSON K, PETO J AND SMITH PG. (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35, 1-39.
35. PLOEGH H, ORR H AND STROMINGER. Major histocompatibility antigens: the human (HLA-A, B, C) and murine (H-2K, H-2D) class-1 molecules. Cell, 24, 287-299.
36. REDONDO M, RUIZ-CABELLO F, CONCHA A, CABRERA T, PEREZ-AYALA M, OLIVA MR AND GARRIDO F. (1991a). Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res., 51, 2463-2468.
37. REDONDO M, CONCHA A, OLDIVIELA R, CUETO A, GONZALEZ A, GARRIDO F AND RUIZ-CABELLO F. (1991b). Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res., 51, 4948-4954.
38. REES R, BUCKLE A, GELTSTHORPE K, JAMES V, POTTER C, ROGERS K AND JACOB G. (1988). Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br. J. Cancer, 57, 374-377.
39. SCHMIDT H, GEKELER V, HAAS H, ENGLER-BLUM G, STEIERT I. PROBST H AND MULLER CA. (1990). Differential regulation of HLA class I genes by interferon. Immunogenetics, 31, 245-252.
40. SOBIN LH. (1982). The World Health Organization's histological classification of lung tumors. A comparison of the first and second editions. Cancer Detect. Prev., 5, 391-406.
41. SPIES T, CERUNDOLO V, COLONNA M, CRESSWELL P, TOWNSEND A AND DEMARS R. (1992). Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature, 355, 644-646.
42. STAM NJ, VROOM T, PETERS P, PATSOORS E AND PLOEGH H. (1990). HLA-A and HLA-B specific monoclonal antibodies reactive with free heavy chains in Western blots, in formalin-fixed paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int. Immunol., 2, 113-125.
43. STEIN B, MOMBURG F, SCHWAZ V, SCHLAG P, MOLDENHAUER G AND MÖLLER P. (1988). Reduction or loss of HLA-A, B, C antigens in colorectal carcinoma appears not to influence survival. Br. J. Cancer, 57, j364-368.
44. TANAKA K, ISSELBACHER K, KHOURY G AND JAY G. (1985). Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science, 228, 26-30.
45. TOWNSEND A, ELLIOT T, CERUNDOLO V, FOSTER L, BARBER B AND TSE A. (1990). Assembly of MHC class I molecules analysed in vitro. Cell, 62, 285-295.
46. TROWSDALE J, HANSEN I, MOCKRIDGE I, BECK S, TOWNSEND A AND KELLY A. (1990). Sequences encoded in the class I region of the MHC related to the 'ABC' superfamily of transporters. Nature, 348, 741-743.
47. WALLICH R, BULBUC O, HÄMMERLING G, KATZAR S, SEGAL S AND FELDMAN M. (1985). De novo expression of H2-K antigens on metastatic tumour cells following H-2 gene transfection results in abrogation of their metastatic properties. Nature, 315, 301-305.
48. WINTZER H-O, BENZING M AND VON KLEIST S. (1990). Lacking prognostic significance of b2-microglobulin, MHC class land class II antigen expression in breast carcinomas. Br. J. Cancer, 62, 289-295.
49. ZINKERNAGEL RM AND DOHERTY P. (1979). MHC-restricted cytotoxic T cells: studies on the biological role of the polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv. Immunol., 27, 51-177.